The aims of this study are to:
1. Identify changes in brain function and structure that correlate with response to
erenumab.
2. Develop models using imaging data +/- clinical data to predict which patients will
respond to erenumab. Pre-treatment and early post-treatment imaging data will be used
separately for predictive modeling.